Glioma

Telix Pharmaceuticals reports significant progress in its precision medicine portfolio, especially in oncology. Key advancements include positive Phase 3 data for TLX591-CDx (Illuccix®) in China for prostate cancer imaging, meeting its primary endpoint and paving the way for a Chinese NDA submission. The company is also nearing NDA resubmission for TLX101-CDx (Pixclara®) in the U.S. and has aligned with the FDA on CMC deficiencies for TLX250-CDx (Zircaix®) BLA. These developments highlight Telix’s strategic focus on radiopharmaceutical innovation and market expansion.